Biotech Stock Review Adds One Medical (ONEM) $28.50 to Watchlist.
It Ain't Cheap at $3.5 Billion.It's Near Doubled Since March 20th.But Look at the Growth.Look at the Cash.Don't Look at the Bottom...
Biotech Stock Review: Mitesco (MITI) $0.03, Report Update
Mitesco to Launch Telehealth Enabled Primary Care Clinic Business with Q4 Rollout Addressing Healthcare Backlog Accentuated by the Second Wave Concerns.
Citius Pharma (CTXR) Seeks Expeditious Pathway Into the Clinic, for CoronaVirus Related Acute Respiratory...
Sumbmits pre-IND Into Coronavirus Treatment Acceleration Program (CTAP).
Citius Announces Pre-IND Submission to FDA Under the Coronavirus...
European Hand Sanitizer Market Expected to Reach $9.4 Billion by 2027.
Growing at a CAGR of 38.4% during 2019–2027.
The European hand sanitizer market was valued at US$ 641.7 million...
Antibiotic-Resistant Super Gonorrhea (CDC).
"We are currently down to one last recommended and effective class of antibiotics, cephalosporins, to treat this common...
CDC’s Worst-Case Coronavirus Model: 214 Million Infected, 1.7 Million Dead (Intelligencer)
A recent CDC projection estimated that the U.S. coronavirus epidemic could infect between 160 million and 214 million people over a period...
Exosomes, Extracellular Vesicles, and the CoronaVirus.
Uploading a Series of Articles on Extracellular Vesicles, Including Potential Effects on the CoronaVirus and ARDS.
Article #1:...
Adding Corbis Pharma (CRBP) $5.55 to Watch List.
Running Clinical Trials Full Steam With $46 Million Banked in Late February.
Not thinly, but lightly traded. Ready,...
Boo Ya. Brokerage Sets $12 Price Target for Athersys (ATHX) $2.96.
A major Wall Street firm that specializes in Bio and Medtech Companies has a $12 price target out on Athersys from one...
Citius (CTXR) and Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
Latest article
Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!
When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's...
GeoVax to Provide Corporate Update on Tuesday May 14, 2024.
Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market...
NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...
Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is...
